Lombristop
Brand names,
Lombristop
Analogs
Lombristop
Brand Names Mixture
Lombristop
Chemical_Formula
C11H16N2O
Lombristop
RX_link
http://www.rxlist.com/cgi/generic3/tocainide.htm
Lombristop
fda sheet
Lombristop
msds (material safety sheet)
Lombristop
Synthesis Reference
No information avaliable
Lombristop
Molecular Weight
192.258 g/mol
Lombristop
Melting Point
246-266 oC
Lombristop
H2O Solubility
1.07E+004 mg/L
Lombristop
State
Solid
Lombristop
LogP
1.308
Lombristop
Dosage Forms
400 mg and 600 mg tablets for oral administration
Lombristop
Indication
For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.
Lombristop
Pharmacology
Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.
Lombristop
Absorption
Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.
Lombristop
side effects and Toxicity
The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.
Lombristop
Patient Information
Lombristop
Organisms Affected
Humans and other mammals